LUPIN LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,759 INR | +7.89% |
|
+11.09% | +32.98% |
| Jul. 04 | INDIA STOCKS-IT leads Indian shares to record highs | RE |
| Jun. 28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| Sales 2024 | 200B 2.4B | Sales 2025 * | 217B 2.6B | Capitalization | 803B 9.62B |
|---|---|---|---|---|---|
| Net income 2024 | 19.14B 229M | Net income 2025 * | 24.08B 289M | EV / Sales 2024 | 3.76 x |
| Net Debt 2024 | 14.67B 176M | Net Debt 2025 * | 3.66B 43.84M | EV / Sales 2025 * | 3.72 x |
| P/E ratio 2024 |
38.6
x | P/E ratio 2025 * |
33.3
x | Employees | 20,933 |
| Yield 2024 |
0.49% | Yield 2025 * |
0.49% | Free-Float | 52.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Lupin Limited
More recommendations
More press releases
More news
| 1 day | +7.89% | ||
| 1 week | +11.09% | ||
| Current month | +8.51% | ||
| 1 month | +11.07% | ||
| 3 months | +9.59% | ||
| 6 months | +25.09% | ||
| Current year | +32.98% |
1 week
1 580.00
1 767.00
1 month
1 543.001 767.00
Current year
1 332.001 767.00
1 year
889.751 767.00
3 years
583.001 767.00
5 years
504.751 767.00
10 years
504.752 129.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 96-12-31 | |
| Director of Finance/CFO | 59 | 07-08-12 | |
Shahin Fesharaki
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 15-10-26 | |
Mark McDade
BRD | Director/Board Member | 69 | 21-01-27 |
| Director/Board Member | 50 | 95-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-04 | 1,759 | +7.89% | 7,086,148 |
| 24-07-03 | 1,631 | -0.13% | 1,236,775 |
| 24-07-02 | 1,633 | +1.04% | 849,266 |
| 24-07-01 | 1,616 | -0.33% | 866,625 |
| 24-06-28 | 1,621 | +2.40% | 1,413,997 |
Delayed Quote NSE India S.E., July 04, 2024 at 07:43 am EDT
More quotes
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
1,760
INR
Average target price
1,599
INR
Spread / Average Target
-9.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +54.07% | 809B | |
| +38.95% | 621B | |
| -7.05% | 351B | |
| +15.44% | 319B | |
| +5.72% | 289B | |
| +14.21% | 238B | |
| -0.45% | 221B | |
| +14.58% | 218B | |
| +7.42% | 166B |
- Stock Market
- Equities
- LUPIN Stock
- LUPIN Stock
